Tranexamic Acid for Women 65 and Older: What You Need to Know About Transitioning to Adult Care

What Tranexamic Acid Does and Why It Is Prescribed to Women

Tranexamic acid stops bleeding by blocking the breakdown of fibrin clots. It binds to plasminogen and plasmin, preventing them from dissolving a clot that has already formed. That mechanism makes it useful in a range of female-relevant clinical situations: heavy menstrual bleeding, surgical hemostasis after gynecologic procedures, bleeding related to uterine fibroids, postpartum hemorrhage, and management of bleeding in women on anticoagulation therapy for whom dose reduction is not possible.

The FDA approved the oral formulation Lysteda specifically for heavy menstrual bleeding (HMB) in 2009, at 1,300 mg three times daily taken for up to five days per menstrual cycle. That approval was based on two randomized controlled trials showing a statistically significant reduction in menstrual blood loss compared with placebo. An intravenous formulation is used in surgical and trauma settings.

For women in their reproductive years, tranexamic acid is often chosen over hormonal therapies when contraception is not needed or hormones are not tolerated. For women moving through perimenopause, it may continue to manage erratic, heavy bleeding episodes when cycles are still occurring. And for women past menopause, it appears primarily in surgical, oncologic, and procedural contexts rather than for cycle-related bleeding.

Why Age 65 Is a Clinical Inflection Point

Age 65 is not arbitrary. It marks the threshold at which renal function has typically declined enough, and polypharmacy has typically accumulated enough, that drug dosing assumptions made in mid-life no longer hold. Glomerular filtration rate declines at approximately 0.75 to 1 mL/min per year after age 40, meaning a woman who had a creatinine clearance of 90 mL/min at 45 may have a clearance of 50 to 60 mL/min by her mid-sixties without any disease.

Tranexamic acid is eliminated almost entirely by the kidneys. When clearance falls, the drug accumulates, and the risk of dose-related adverse effects, including seizures and thrombosis, increases.

The Postmenopausal Bleeding Context

A woman who is postmenopausal and experiencing vaginal bleeding should be evaluated for endometrial pathology before tranexamic acid is started or continued. Tranexamic acid does not treat the cause of bleeding. If an endometrial cancer or polyp is present, using an antifibrinolytic to suppress the bleeding without investigation delays diagnosis. ACOG Practice Bulletin No. 128 recommends endometrial sampling for postmenopausal women with uterine bleeding before initiating any bleeding-suppression strategy.

How Renal Function Changes the Dose After 65

Tranexamic acid's prescribing information specifies dose reductions tied directly to creatinine clearance (CrCl). The standard oral dose of 1,300 mg three times daily applies only to women with CrCl at or above 50 mL/min. Below that threshold, the recommended adjustments are:

| Creatinine Clearance | Recommended Oral Dose | |---|---| | <50 mL/min | 1,300 mg twice daily | | <30 mL/min | 1,300 mg once daily | | <10 mL/min | 650 mg once daily |

These adjustments are not optional. Accumulation at full dose in a woman with reduced renal clearance increases seizure risk, a side effect that is already more common in older patients receiving high or repeated doses.

Getting a Current Creatinine Clearance

Serum creatinine alone can be misleading in older women. Muscle mass declines with age, so creatinine production falls, and serum creatinine may look normal even when true clearance is significantly reduced. The Cockcroft-Gault equation, which factors in age, weight, and sex, gives a better estimate for dosing purposes than eGFR alone. Ask your clinician to calculate CrCl using Cockcroft-Gault before starting or renewing tranexamic acid.

IV Dosing in Surgical Settings

In surgical or trauma settings, intravenous tranexamic acid is dosed differently and adjusted separately. The WOMAN trial (2017), which enrolled over 20,000 women with postpartum hemorrhage, used a 1 g IV dose followed by a second 1 g dose if bleeding continued. That population was reproductive age, not geriatric, and those doses were not evaluated in older surgical patients with reduced renal function. Surgical teams managing women 65 and older should apply the same renal-based dose adjustments described above.

Thromboembolic Risk in Women 65 and Older

Tranexamic acid stabilizes clots, which is what makes it useful. That same mechanism raises a legitimate question about venous thromboembolism (VTE) risk, particularly in older women who already have a higher baseline clot risk than younger women.

The clinical evidence is somewhat reassuring but not fully settled. A 2019 meta-analysis in The Lancet examining tranexamic acid in trauma and surgery found no statistically significant increase in VTE risk when the drug was used at recommended doses. The menstrual-bleeding trials showed no increased clot risk over placebo. But those trials enrolled primarily healthy women of reproductive age, and the data are not directly transferable to women 65 and older who carry additional VTE risk factors.

Female-Specific VTE Risk Factors to Assess at 65+

Before continuing or starting tranexamic acid after 65, a clinician should review:

• History of deep vein thrombosis or pulmonary embolism
• Current or recent use of systemic hormone therapy (HRT/MHT), which itself carries a thrombotic signal, particularly with oral estrogen
• Factor V Leiden, prothrombin gene mutation, or other inherited thrombophilia
• Immobility, recent surgery, or active malignancy
• Antiphospholipid antibody syndrome, which is more common in women than men and can persist into and beyond menopause

The prescribing label for Lysteda states that the drug is contraindicated in women with active thromboembolic disease and in those with a history of thrombosis or thromboembolism, including retinal vein or retinal artery occlusion. This is an absolute contraindication, not a relative one.

Hormone Therapy and Tranexamic Acid in the Same Patient

Many women around 65 are either still on menopausal hormone therapy or have recently stopped. Oral estrogen increases clot risk by altering hepatic clotting factor synthesis. Whether the combination of oral MHT and tranexamic acid produces additive VTE risk has not been directly studied in a dedicated trial. Given the biological plausibility of additive risk, clinicians at WomanRx generally recommend using transdermal rather than oral estrogen in women who also need tranexamic acid, because transdermal estradiol does not appear to increase VTE risk to the same degree as oral forms.

This is a practical framework for the transition-of-care review: when a woman moves from a gynecology or hematology specialist to a primary or geriatric care provider, the new clinician should ask three questions simultaneously: (1) What is her current CrCl? (2) Is she on any thrombogenic medications, including oral HRT, tamoxifen, or raloxifene? (3) Has her indication for tranexamic acid changed now that she is fully postmenopausal?

Transition to Adult Care: What It Means After 65 and Why It Often Goes Wrong

The phrase "transition to adult care" typically describes the move from pediatric to adult medicine for young people with chronic conditions. In the geriatric context, it describes something different but equally high-stakes: the shift of prescribing authority and clinical ownership from a specialist, often a gynecologist, hematologist, or ob-gyn, to a primary care physician, internal medicine specialist, or geriatrician as a woman's healthcare needs shift from reproductive to aging-related priorities.

This transition is where dosing errors and contraindicated combinations most often appear. A specialist who prescribed Lysteda at 1,300 mg three times daily for a 55-year-old with normal renal function may not flag that prescription for revision when she turns 66 and her creatinine clearance has dropped to 38 mL/min. The new primary clinician who inherits the medication list may assume the specialist reviewed it recently.

What a Safe Transition Should Include

A structured handoff for a woman on tranexamic acid should document:

• The original indication and whether it still applies
• The most recent creatinine clearance with the date of the lab
• The calculated dose tier and the prescribed dose
• Any contraindications that have developed since the prescription was written (new DVT, new diagnosis of retinal vein occlusion, new malignancy with thrombotic risk)
• Concurrent medications that interact with clotting or fibrinolysis

ACOG's clinical guidance on perimenopause management does not yet include a dedicated transition-of-care checklist for antifibrinolytic therapy in older women, which reflects a genuine gap in structured guidance.

Polypharmacy Interactions to Flag

Women 65 and older take more medications on average than any other demographic. Tranexamic acid has few direct pharmacokinetic interactions because it is cleared renally without hepatic metabolism, but functional interactions matter:

• Combined oral contraceptives or hormone therapy: Additive thrombotic risk as discussed above.
• Factor IX complex concentrates or anti-inhibitor coagulant concentrates: Concurrent use with tranexamic acid may increase risk of thrombosis and is generally avoided.
• All-trans retinoic acid (tretinoin for APL): This combination has been associated with fatal thrombotic events in case reports and should be avoided.

Conditions Where Tranexamic Acid Remains Relevant After 65

Heavy menstrual bleeding is the most common indication in reproductive-age women, but it is rarely the indication after 65. The drug remains clinically useful in older women in several specific situations.

Gynecologic and Oncologic Bleeding

Women with cervical, uterine, or vaginal cancers sometimes experience significant tumor-related bleeding. Tranexamic acid, applied topically (soaked gauze or oral administration), can reduce bleeding episodes in palliative or pre-surgical settings. A 2020 Cochrane review on antifibrinolytics for heavy menstrual bleeding confirmed tranexamic acid's efficacy for reducing blood loss, though most included studies were in reproductive-age women.

Postoperative Hemostasis

Older women undergoing gynecologic surgeries, joint replacements, or cardiac procedures may receive tranexamic acid intraoperatively or perioperatively to reduce blood loss and transfusion requirements. In this context, renal dosing adjustments are applied by the anesthesia or surgical team, but the primary care clinician should document the exposure in the medication history.

Hereditary Bleeding Disorders

Von Willebrand disease (VWD) affects approximately 1% of the general population and is often underdiagnosed in women. Tranexamic acid is a first-line option for mucosal bleeding in VWD. Women with VWD who reach menopause and then require dental or minor surgical procedures continue to need tranexamic acid for procedural coverage, and the same renal-adjusted dosing applies.

Female Pattern Hair Loss and Off-Label Topical Use

Topical tranexamic acid has emerged as an off-label treatment for melasma and, more recently, female pattern hair loss (androgenetic alopecia). A 2020 randomized trial published in JAAD found topical tranexamic acid reduced hyperpigmentation. Systemic absorption from topical formulations is lower than oral doses, but it has not been rigorously quantified in older women with thin skin and altered barrier function. This is an evidence gap. Older women using topical tranexamic acid preparations should inform their primary clinician.

Pregnancy and Lactation Safety

This section applies to the small but real population of women in their early-to-mid sixties who may still be perimenopausal and capable of pregnancy, or to women of any age reviewing this drug for completeness.

Pregnancy

Tranexamic acid crosses the placenta. It is listed in the FDA's older pregnancy category system as Category B, meaning animal studies showed no fetal harm but adequate human studies are lacking. Human data are most available from its use in postpartum hemorrhage, where it is given after delivery, not during pregnancy. Use during the first trimester is not well-studied and should be reserved for situations where the benefit clearly outweighs unknown risk. The drug is not teratogenic in animal models at therapeutic doses, but caution is warranted.

Contraception Requirements

Tranexamic acid is not itself a teratogen requiring mandatory contraception in the way that isotretinoin or valproate does. However, women of childbearing potential who are prescribed tranexamic acid for heavy menstrual bleeding should discuss contraception separately, because the underlying condition (HMB) may itself prompt a conversation about hormonal options that also provide contraception.

For the perimenopausal woman who is uncertain whether she is still ovulating, reliable contraception should continue until 12 months of amenorrhea have elapsed, per ACOG and The Menopause Society guidance. Tranexamic acid taken for perimenopausal heavy bleeding does not protect against pregnancy.

Lactation

Tranexamic acid is transferred into breast milk in small amounts. A pharmacokinetic study found milk concentrations of approximately 1% of the maternal serum level, which is considered a low relative infant dose. LactMed classifies it as likely compatible with breastfeeding at the doses used for menstrual bleeding. Women who are breastfeeding and prescribed tranexamic acid postpartum for hemorrhage management can continue nursing. If concerned, timing feeds to the trough of the dosing interval (just before the next dose) reduces infant exposure.

Who This Drug Is Right For and Who Should Avoid It

Women Aged 65+ Who May Benefit

• Women with inherited bleeding disorders (VWD, platelet function disorders) who need procedural coverage
• Women undergoing gynecologic or orthopedic surgery where perioperative blood loss reduction is indicated
• Women with tumor-related or post-procedural bleeding in a palliative context
• Women who are perimenopausal (not yet fully postmenopausal) with ongoing heavy menstrual bleeding and no hormonal therapy option

Women Aged 65+ Who Should Not Use This Drug

• Women with active VTE or a personal history of DVT, pulmonary embolism, or retinal vascular occlusion
• Women with subarachnoid hemorrhage (risk of cerebral ischemia with antifibrinolytics)
• Women with creatinine clearance below 10 mL/min on dialysis, where dosing becomes highly individualized and specialist oversight is mandatory
• Women receiving all-trans retinoic acid for acute promyelocytic leukemia

The Evidence Gap for Women 65 and Older

Women over 65 have been consistently underrepresented in the clinical trials that established tranexamic acid's efficacy and safety profile. The two key menstrual-bleeding trials enrolled women aged 18 to 49. The WOMAN trial enrolled postpartum women. Most surgical trials included participants across a broad age range but did not stratify safety outcomes by sex and age simultaneously. This means that the thromboembolic risk estimates, the dose-response curves, and the seizure threshold data applied to older women are largely extrapolated from younger populations or mixed-sex surgical cohorts, not directly studied in women 65 and older. Clinicians and patients making decisions about this drug in this age group should understand that the evidence base is thinner than the prescribing label implies.

Monitoring and Follow-Up Recommendations

Once tranexamic acid is initiated or continued in a woman 65 and older, monitoring should be systematic rather than reactive.

Renal function: Check creatinine clearance at baseline, at 6 months, and annually. Recalculate the dose tier each time. A woman who was dosed correctly at 65 may need a further reduction by 70 if clearance has continued to decline.

Symptom review: Ask specifically about leg swelling, chest pain, and sudden vision changes at every visit. These may indicate VTE or retinal vascular occlusion. Tranexamic acid should be stopped immediately if any of these develop.

Indication reassessment: If the original indication was perimenopausal heavy menstrual bleeding, reassess at 12 months of amenorrhea. A woman who is now confirmed postmenopausal does not need tranexamic acid for that indication. Any new bleeding in a confirmed postmenopausal woman requires endometrial evaluation before the drug is continued or restarted.

Neurologic symptoms: Seizures are rare at oral menstrual-bleeding doses but have been reported at high IV doses. Older women with lower seizure thresholds due to prior stroke, dementia medications, or other neurologic conditions should be monitored more carefully.

The American Geriatrics Society Beers Criteria, updated in 2023, does not list tranexamic acid as a potentially inappropriate medication in older adults, which means it is not automatically flagged by pharmacist review systems. That absence of a Beers flag does not mean the drug is low-risk in this population. Renal dosing adjustments and VTE risk assessment remain the clinician's responsibility.